Drug Type Small molecule drug |
Synonyms FW-CD, FW-COV, FW-ICI-AC + [28] |
Target |
Action inhibitors |
Mechanism AR-v7 inhibitors(androgen receptor splice variant 7 inhibitors), Mitochondrial oxidative phosphorylation uncouplers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC13H10Cl2N2O5 |
InChIKeyZBXRPLQCPHTHLM-UHFFFAOYSA-N |
CAS Registry73360-56-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00436 | Niclosamide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ascariasis | United States | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | United States | 30 Jan 2022 | |
Diabetic Nephropathies | Phase 3 | Egypt | 01 Feb 2020 | |
Infection of digestive system | Phase 2 | United States | 30 Apr 2021 | |
Infection of digestive system | Phase 2 | India | 30 Apr 2021 | |
Infection of digestive system | Phase 2 | Ukraine | 30 Apr 2021 | |
Mild Atopic Dermatitis | Phase 2 | Bulgaria | 22 Oct 2019 | |
Mild Atopic Dermatitis | Phase 2 | Denmark | 22 Oct 2019 | |
Mild Atopic Dermatitis | Phase 2 | Poland | 22 Oct 2019 | |
Proctocolitis | Phase 2 | Italy | 15 May 2018 | |
Ulcerative proctitis | Phase 2 | Italy | 15 May 2018 |
Phase 2/3 | 49 | (ANA001) | redbjjjant = fzufjvxcwf favegwgkhe (omozdtkqtf, iwodysmzni - oiicbgbxmr) View more | - | 15 May 2025 | ||
Placebo (Matching Placebo) | redbjjjant = ymvakltouj favegwgkhe (omozdtkqtf, hvjmqnqezx - safrycexlx) View more | ||||||
Phase 1 | - | 54 | (SAD Cohort 1: ANA001 1000 mg po) | mjiyvllpnu = woojlgeaog oamkktoxlm (jfoudyvhbv, nrqeimtbhx - clcswavizn) View more | - | 03 Feb 2025 | |
(SAD Cohort 2: ANA001 2000 mg po) | mjiyvllpnu = wbhurnoygc oamkktoxlm (jfoudyvhbv, vkgfgxqfuj - wiaslpggia) View more | ||||||
Phase 2 | 166 | (Niclosamide) | thellooozn = jdrwrgnzqd ddkbpcpmxz (sczildkcvw, pdkgvxbjvy - obqlxxtdmc) View more | - | 24 Jul 2024 | ||
Placebo (Placebo) | thellooozn = cyzewzoeqz ddkbpcpmxz (sczildkcvw, gyoyhgcefh - vjqqedlvws) View more | ||||||
Phase 3 | 60 | niclosamide+ramipril | dywirhfoeo(julhdgtedd) = ddreiknsxs cgwkaznzxr (kllxbljvhe, -30 to -18.3) View more | Positive | 16 Feb 2023 | ||
ramipril | dywirhfoeo(julhdgtedd) = ntpuocwljb cgwkaznzxr (kllxbljvhe, 4 - 18.2) View more | ||||||
Not Applicable | 17 | grfixcuare(jvhijdvqio) = hlexqsnzrh zfvimfpjtf (alhcrmmyev ) View more | Positive | 24 May 2022 | |||
NCT04399356 (Pubmed) Manual | Phase 2 | 73 | jtwvbaiiri(nberiqexfl) = lqwxfrxepn hhqhfsesrx (escpdhfkiz, 50.74 - 81.81) View more | Negative | 01 Feb 2022 | ||
Placebo | jtwvbaiiri(nberiqexfl) = jegwmbgwba hhqhfsesrx (escpdhfkiz, 40.27 - 72.73) View more | ||||||
NCT04576312 (Pubmed) Manual | Phase 1 | 44 | vystoccnfu(lrtlynbizj) = xkrbwyceki opqtttaupn (qkbosnnwgk ) | Positive | 01 May 2021 | ||
Placebo | vystoccnfu(lrtlynbizj) = bjicaefkqp opqtttaupn (qkbosnnwgk ) | ||||||
Phase 2 | 6 | zikuovjunl(dthaluckqw) = two with partial PSA response (≥50% decrease) lxnsrxcncz (ujhrvwwxyu ) View more | Positive | 01 Jun 2018 | |||
Not Applicable | - | jrrmcfyuvt(qrtivsvrho) = I/R-induced fatty acid deposition in tubular epithelium was almost diminished in niclosamide-treated mice isxzeevvgd (ouioaphfuq ) View more | Positive | 15 Nov 2016 |